BenevolentAI director takes chair at Stevenage Bioscience Catalyst
Stevenage Bioscience Catalyst, a leading location for development and commercialisation of cutting-edge therapeutics, reveals that Professor Jackie Hunter is to take the role of chair in September.
Jackie is currently a director at BenevolentAI and has over 30 years of experience in the bioscience research sector, working across academia and industry, including leading neurology and gastrointestinal drug discovery and early clinical development for GlaxoSmithKline.
BenevolentAI is a British-held company using AI to augment the research capabilities of drug scientists, radically changing the way R & D is done.
Before joining BenevolentAI, Jackie was chief executive of the Biotechnology and Biological Sciences Research Council. She has been recognised by Forbes Magazine as one of the Top 20 Women Advancing AI Research and named in MedicineMaker’s Power List 100 for 2019.
She is a member of the Biomedical Board for A*Star in Singapore, the Science Advisory Board for the Data Science Institute at Imperial College London, a board director of the UK BioIndustry Association and recently joined the Technology Advisory Board for British Petroleum plc.
She is also a visiting Professor at Imperial College and at St George’s Hospital Medical School. She has held Non-Executive Board positions for both private and public companies.
Dr Sally Ann Forsyth, CEO at SBC said: “With her years of expertise in the sector, both academic and commercial, Jackie will provide an invaluable insight in the role. She is ideally placed to support the growth of our companies and our campus.”
Professor Hunter added: “I am excited to be joining SBC as chair at such a dynamic time for the world-leading campus and very much look forward to working with Sally Ann and her team.”
Stevenage Bioscience Catalyst is a world-leading science park of global significance and is at the centre of the largest cluster of cell and gene therapy companies in Europe.
Since opening in 2012, it has attracted over 45 high-profile occupier businesses and world-class research organisations to Stevenage which together have raised over £1.5 billion of investment.
This includes collaborators based at the Cell and Gene Therapy Catapult Manufacturing Centre which is currently undergoing expansion to help support up to 12 cell and gene therapy companies.